Glenmark Pharmaceuticals Ltd. (GLENMARK)

Overview

Glenmark Pharmaceuticals Limited operates as an expansive pharmaceutical company that has created a significant mark both on the Indian pharmaceutical landscape and on a global scale. Incorporated in 1977 and headquartered in Mumbai, India, Glenmark Pharmaceuticals has evolved into a major player in the pharma industry, extending its reach across North America, Latin America, Europe, Japan, and various international markets. The company's operations envelop the development, manufacturing, and marketing of a wide range of pharmaceutical products. Glenmark takes pride in its diversified product portfolio that spans across several therapeutic areas, including dermatology, respiratory, and oncology, further backed by a substantial offering of active pharmaceutical ingredients. With a dedicated focus on innovation and quality, the company has established a strong foothold in both the branded and generic formulations sectors, catering to the healthcare needs of diverse patient populations around the globe.

Products and Services

• ISB 2001 - A BCMA x CD38 x CD3 trispecific antibody currently in Phase 1 clinical trial aimed at treating oncology patients. This innovative therapeutic approach signifies Glenmark's commitment to advancing cancer treatment solutions.
• GRC 39815 - This retinoid-related orphan receptor gamma t inverse agonist is undergoing Phase 1 clinical trials, targeting the treatment of chronic obstructive pulmonary disease (COPD). It exemplifies Glenmark’s pursuit of novel therapies in respiratory care.
• GRC 54276 - In Phase 1 clinical trial, this hematopoietic progenitor kinase 1 inhibitor is aimed at the treatment of solid tumors, underscoring the company's ongoing efforts in expanding its oncology pipeline.
• ISB 1342 - A CD38 X CD3 bispecific antibody in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. This product highlights Glenmark's focus on addressing critical needs in cancer care.
• ISB 1442 - Also in the oncology realm, this CD38 x CD47 immune cell engager is being tested in Phase 1 clinical trials for relapsed/refractory multiple myeloma, representing another of Glenmark's innovations in cancer therapy.
• ISB 880 - An IL-1RAP antibody currently in Phase 1 clinical trial intended for the treatment of autoimmune diseases. This development reflects the company's dedication to improving treatment options in autoimmune care.
• ISB 830 - An OX40 antagonist in Phase 2 clinical trial for atopic dermatitis. This product exemplifies Glenmark's commitment to advancing dermatological care through novel therapeutic agents.
• Ryaltris nasal spray - Approved for the treatment of seasonal allergic rhinitis, Ryaltris nasal spray is an example of Glenmark’s market-ready products that provide immediate relief to patients suffering from allergic conditions.